CYP1A2*1F and GSTM1 alleles are associated with susceptibility to porphyria cutanea tarda

Molecular Medicine

Volumn 17, Issue 3-4, 2011, Pages 241-247

  Wickliffe, Jeffrey K ^a,d   Abdel Rahman, Sherif Z ^a,b   Lee, Chul ^a   Kormos Hallberg, Csilla ^a   Sood, Gagan ^c,e   Rondelli, Catherine M ^a,b   Grady, James J ^a   Desnick, Robert J ^f   Anderson, Karl E ^a,c  

^a Departments of Preventive Medicine and Community Health   (United States)

^b Departments of Obstetrics and Gynecology   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d TULANE UNIVERSITY   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1A2 1F; CYTOCHROME P450 2E1; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; PORPHYRIN; UNCLASSIFIED DRUG; UROPORPHYRINOGEN DECARBOXYLASE; GLUTATHIONE S-TRANSFERASE M1; GLUTATHIONE TRANSFERASE; ISOENZYME;

ALLELE; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; ONSET AGE; PATHOGENESIS; PORPHYRIA CUTANEA TARDA; PORPHYRIA CUTANEA TARDA TYPE 1; PORPHYRIA CUTANEA TARDA TYPE 2; PRIORITY JOURNAL; PROMOTER REGION; URINALYSIS; WILD TYPE; GENE LINKAGE DISEQUILIBRIUM; GENETIC PREDISPOSITION; GENETICS; RISK FACTOR;

ALLELES; CYTOCHROME P-450 CYP1A2; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; ISOENZYMES; LINKAGE DISEQUILIBRIUM; PORPHYRIA CUTANEA TARDA; PROMOTER REGIONS, GENETIC; RISK FACTORS;

EID: 79952919700     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2010.00130     Document Type: Article

References (44)

1. Anderson KE, Sassa S, Bishop DF, Desnick RJ. (2001) Disorders of heme biosynthesis: X-linked sideroblastic anemias and the porphyrias. In: The Metabolic & Molecular Basis of Inherited Disease. 8th ed. Vol. 2. Scriver CR, Beaudet AL, Sly WS, Valle D (eds.) McGraw-Hill, New York, pp. 2991-3062.
2. Jalil S, Grady JJ, Lee C, Anderson KE. (2010) Associations Among Behavior-Related Susceptibility Factors in Porphyria Cutanea Tarda. Clin. Gastroenterol. Hepatol. 2010 8:297-302.
3. Munoz-Santos C, et al. (2010) Familial and sporadic porphyria cutanea tarda: clinical and biochemical features and risk factors in 152 patients. Medicine (Baltimore). 89:69-74.
4. Bleiberg J, Wallen M, Brodkin R, Applebaum I. (1964) Industrially acquired porphyria. Arch. Dermatol. 89:793-7.
5. Can C, Nigogosyan G. (1963) Acquired toxic porphyria cutanea tarda due to hexachlorobenzene. Report of 348 cases caused by this fungicide. JAMA. 183:88-91.
6. Daniell WE, et al. (1997) Environmental chemical exposures and disturbances of heme synthesis. Environmental Health Perspectives 105 Suppl 1:37-53.
7. Elder GH. (2003) Porphyria cutanea tarda and related disorders. In: Kadish KM, Smith K, Guilard R (eds.) Porphyrin Handbook, Part II. Academic Press, San Diego, pp. 67-92. Chapter 88.
8. Elder GH, Urquhart AJ, de Salamanca RE, Munoz JJ, Bonkovsky HL. (1985) Immunoreactive uroporphyrinogen decarboxylase in the liver in porphyria cutanea tarda. Lancet. 2:229-33.
9. Phillips JD, Bergonia HA, Reilly CA, Franklin MR, Kushner JP. (2007) A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc. Natl. Acad. Sci. U. S. A. 104:5079-84.
10. Gorman N, et al. (1999) Role of small differences in CYP1A2 in the development of uroporphyria produced by iron and 5-aminolevulinate in C57BL/6 and SWR strains of mice. Biochem. Pharmacol. 58:375-82.
11. Sinclair PR, et al. (1998) Uroporphyria produced in mice by iron and 5-aminolaevulinic acid does not occur in Cyp1a2(-/-) null mutant mice. Biochem. J. 330:149-53.
12. Sinclair PR, et al. (2000) CYP1A2 is essential in murine uroporphyria caused by hexachlorobenzene and iron. Toxicol. Appl. Pharmacol. 162:60-7.
13. Nichols RC, et al. (2003) Uroporphyrin accumulation in hepatoma cells expressing human or mouse CYP1A2: relation to the role of CYP1A2 in human porphyria cutanea tarda. Biochem. Pharmacol. 65:545-50.
14. Castorena-Torres F, et al. (2005) CYP1A2 phenotype and genotype in a population from the carboniferous region of Coahuila, Mexico. Toxicol. Lett. 156:331-9.
15. Han XM, et al. (2002) Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2. Br. J. Clin. Pharmacol. 54:540-3.
16. Sachse C, Brockmoller J, Bauer S, Roots I. (1999) Functional significance of a C->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol. 47:445-9.
17. Christiansen L, et al. (2000) Association between CYP1A2 polymorphism and susceptibility to porphyria cutanea tarda. Hum. Genet. 107:612-4.
18. Fontanellas A, et al. (2010) Smoking but not homozygosity for CYP1A2 g-163A allelic variant leads to earlier disease onset in patients with sporadic porphyria cutanea tarda. Exp. Dermatol. 19:e326-8.
19. Dereure O, et al. (2004) No significant association between CYP1A2 polymorphism and porphyria cutanea tarda. Acta. Derm. Venereol. 84:254-5.
20. Alexandrie AK, et al. (2000) CYP1A1 and GSTM1 polymorphisms affect urinary 1-hydroxypyrene levels after PAH exposure. Carcinogenesis. 21:669-76.
21. Alexandrov K, et al. (2002) CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers' lung: comparison with aromatic/hydrophobic adduct formation. Carcinogenesis. 23:1969-77.
22. Chen Y, et al. (2006) Association of polymorphisms in AhR, CYP1A1, GSTM1, and GSTT1 genes with levels of DNA damage in peripheral blood lymphocytes among coke-oven workers. Cancer Epidemiol. Biomarkers Prev. 15:1703-7.
23. Schwarz D, et al. (2000) Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 10:519-30.
24. Shah PP, Saurabh K, Pant MC, Mathur N, Parmar D. (2009) Evidence for increased cytochrome P450 1A1 expression in blood lymphocytes of lung cancer patients. Mutat. Res. 670:74-8.
25. Gardlo K, et al. (2003) Cytochrome p450A1 polymorphisms in a Caucasian population with porphyria cutanea tarda. Exp. Dermatol. 12:843-8.
26. Seidegard J, Vorachek WR, Pero RW, Pearson WR. (1988) Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc. Natl. Acad. Sci. U. S. A. 85:7293-7.
27. Binkova B, et al. (2007) PAH-DNA adducts in environmentally exposed population in relation to metabolic and DNA repair gene polymorphisms. Mutat. Res. 620:49-61.
28. Aklillu E, et al. (2003) Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol. Pharmacol. 64:659-69.
29. Cascorbi I, Brockmoller J, Roots I. (1996) A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res. 56:4965-9.
30. Chida M, et al. (1999) Detection of three genetic polymorphisms in the 5′-flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn. J. Cancer Res. 90:899-902.
31. Spurr NK, Gough AC, Stevenson K, Wolf CR. (1987) Msp-1 polymorphism detected with a cDNA probe for the P-450 I family on chromosome 15. Nucleic Acids Res. 15:5901.
32. Watanabe J, et al. (1990) PstI and RsaI RFLPs in complete linkage disequilibrium at the CYP2E gene. Nucleic Acids Res. 18:7194.
33. Zhang ZY, Fasco MJ, Huang L, Guengerich FP, Kaminsky LS. (1996) Characterization of purified human recombinant cytochrome P4501A1-Ile462 and -Val462: assessment of a role for the rare allele in carcinogenesis. Cancer Res. 56:3926-33.
34. Egger NG, et al. (2002) Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. Dig. Dis. Sci. 47:419-26.
35. Badenas C, et al. (2009) Identification and characterization of novel uroporphyrinogen decarboxylase gene mutations in a large series of porphyria cutanea tarda patients and relatives. Clin. Genet. 75:346-53.
36. Abdel-Rahman SZ, el-Zein RA, Anwar WA, Au WW. (1996) A multiplex PCR procedure for polymorphic analysis of GSTM1 and GSTT1 genes in population studies. Cancer Lett. 107:229-33.
37. Ding K, Zhou K, He F, Shen Y. (2003) LDA-a java-based linkage disequilibrium analyzer. Bioinformatics. 19:2147-8.
38. Franklin MR, Phillips JD, Kushner JP. (1997) Cytochrome P450 induction, uroporphyrinogen decarboxylase depression, porphyrin accumulation and excretion, and gender influence in a 3-week rat model of porphyria cutanea tarda. Toxicol. Appl. Pharmacol. 147:289-99.
39. International HapMap Consortium. (2003) The International HapMap Project. Nature. 426:789-96.
40. Ahmad S, Agrawal R, Agrawal DK, Rao GS. (2000) Bioreactivity of glutathionyl hydroquinone with implications to benzene toxicity. Toxicology. 150:31-9.
41. Brunmark A, Cadenas E. (1988) Reductive addition of glutathione to p-benzoquinone, 2-hydroxyp-benzoquinone, and p-benzoquinone epoxides. Effect of the hydroxy- and glutathionyl substituents on p-benzohydroquinone autoxidation. Chem. Biol. Interact. 68:273-98.
42. Brunmark A, Cadenas E, Segura-Aguilar J, Lind C, Ernster L. (1988) DT-diaphorase-catalyzed twoelectron reduction of various p-benzoquinoneand 1,4-naphthoquinone epoxides. Free Radic. Biol. Med. 5:133-43.
43. Dekant W, Vamvakas S. (1993) Glutathionedependent bioactivation of xenobiotics. Xenobiotica. 23:873-87.
44. Monks TJ, et al. (1990) Glutathione conjugate mediated toxicities. Toxicol. Appl. Pharmacol. 106:1-19.